Rishi K Gupta1, Marc Lipman2,3,4, Charlotte Jackson1, Alice J Sitch5,6, Jo Southern7, Francis Drobniewski8, Jonathan J Deeks5,6, Chuen-Yan Tsou7, Chris Griffiths9, Jennifer Davidson7, Colin Campbell7, Oliver Stirrup1, Mahdad Noursadeghi10, Heinke Kunst11,12, Pranab Haldar13, Ajit Lalvani14, Ibrahim Abubakar1. 1. Institute for Global Health. 2. UCL-TB. 3. UCL Respiratory, and. 4. Royal Free London National Health Service (NHS) Foundation Trust, London, United Kingdom. 5. National Institute for Health Research Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, United Kingdom. 6. Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom. 7. Tuberculosis Unit, Public Health England, Colindale, London, United Kingdom. 8. Section of Infectious Diseases and Immunity and. 9. Barts Institute of Population Health Sciences and. 10. Division of Infection and Immunity, University College London, London, United Kingdom. 11. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. 12. Department of Respiratory Medicine, Barts Health NHS Trust, London, United Kingdom; and. 13. Respiratory Biomedical Research Centre, Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom. 14. Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College, London, United Kingdom.
Abstract
Rationale: Development of diagnostic tools with improved predictive value for tuberculosis (TB) is a global research priority. Objectives: We evaluated whether implementing higher diagnostic thresholds than currently recommended for QuantiFERON Gold-in-Tube (QFT-GIT), T-SPOT.TB, and the tuberculin skin test (TST) might improve prediction of incident TB. Methods: Follow-up of a UK cohort of 9,610 adult TB contacts and recent migrants was extended by relinkage to national TB surveillance records (median follow-up 4.7 yr). Incidence rates and rate ratios, sensitivities, specificities, and predictive values for incident TB were calculated according to ordinal strata for quantitative results of QFT-GIT, T-SPOT.TB, and TST (with adjustment for prior bacillus Calmette-Guérin [BCG] vaccination).Measurements and Main Results: For all tests, incidence rates and rate ratios increased with the magnitude of the test result (P < 0.0001). Over 3 years' follow-up, there was a modest increase in positive predictive value with the higher thresholds (3.0% for QFT-GIT ≥0.35 IU/ml vs. 3.6% for ≥4.00 IU/ml; 3.4% for T-SPOT.TB ≥5 spots vs. 5.0% for ≥50 spots; and 3.1% for BCG-adjusted TST ≥5 mm vs. 4.3% for ≥15 mm). As thresholds increased, sensitivity to detect incident TB waned for all tests (61.0% for QFT-GIT ≥0.35 IU/ml vs. 23.2% for ≥4.00 IU/ml; 65.4% for T-SPOT.TB ≥5 spots vs. 27.2% for ≥50 spots; 69.7% for BCG-adjusted TST ≥5 mm vs. 28.1% for ≥15 mm).Conclusions: Implementation of higher thresholds for QFT-GIT, T-SPOT.TB, and TST modestly increases positive predictive value for incident TB, but markedly reduces sensitivity. Novel biomarkers or validated multivariable risk algorithms are required to improve prediction of incident TB.
Rationale: Development of diagnostic tools with improved predictive value for tuberculosis (TB) is a global research priority. Objectives: We evaluated whether implementing higher diagnostic thresholds than currently recommended for QuantiFERON Gold-in-Tube (QFT-GIT), T-SPOT.TB, and the tuberculin skin test (TST) might improve prediction of incident TB. Methods: Follow-up of a UK cohort of 9,610 adult TB contacts and recent migrants was extended by relinkage to national TB surveillance records (median follow-up 4.7 yr). Incidence rates and rate ratios, sensitivities, specificities, and predictive values for incident TB were calculated according to ordinal strata for quantitative results of QFT-GIT, T-SPOT.TB, and TST (with adjustment for prior bacillus Calmette-Guérin [BCG] vaccination).Measurements and Main Results: For all tests, incidence rates and rate ratios increased with the magnitude of the test result (P < 0.0001). Over 3 years' follow-up, there was a modest increase in positive predictive value with the higher thresholds (3.0% for QFT-GIT ≥0.35 IU/ml vs. 3.6% for ≥4.00 IU/ml; 3.4% for T-SPOT.TB ≥5 spots vs. 5.0% for ≥50 spots; and 3.1% for BCG-adjusted TST ≥5 mm vs. 4.3% for ≥15 mm). As thresholds increased, sensitivity to detect incident TB waned for all tests (61.0% for QFT-GIT ≥0.35 IU/ml vs. 23.2% for ≥4.00 IU/ml; 65.4% for T-SPOT.TB ≥5 spots vs. 27.2% for ≥50 spots; 69.7% for BCG-adjusted TST ≥5 mm vs. 28.1% for ≥15 mm).Conclusions: Implementation of higher thresholds for QFT-GIT, T-SPOT.TB, and TST modestly increases positive predictive value for incident TB, but markedly reduces sensitivity. Novel biomarkers or validated multivariable risk algorithms are required to improve prediction of incident TB.
Authors: Jennifer Roe; Cristina Venturini; Rishi K Gupta; Celine Gurry; Benjamin M Chain; Yuxin Sun; Jo Southern; Charlotte Jackson; Marc C Lipman; Robert F Miller; Adrian R Martineau; Ibrahim Abubakar; Mahdad Noursadeghi Journal: Clin Infect Dis Date: 2020-02-14 Impact factor: 9.079
Authors: Hilary S Whitworth; Amarjit Badhan; Aime A Boakye; Yemisi Takwoingi; Melanie Rees-Roberts; Christopher Partlett; Heather Lambie; John Innes; Graham Cooke; Marc Lipman; Christopher Conlon; Derek Macallan; Felix Chua; Frank A Post; Martin Wiselka; Gerrit Woltmann; Jonathan J Deeks; Onn Min Kon; Ajit Lalvani Journal: Lancet Infect Dis Date: 2019-01-14 Impact factor: 25.071
Authors: Sara Suliman; Ethan G Thompson; Jayne Sutherland; January Weiner; Martin O C Ota; Smitha Shankar; Adam Penn-Nicholson; Bonnie Thiel; Mzwandile Erasmus; Jeroen Maertzdorf; Fergal J Duffy; Philip C Hill; E Jane Hughes; Kim Stanley; Katrina Downing; Michelle L Fisher; Joe Valvo; Shreemanta K Parida; Gian van der Spuy; Gerard Tromp; Ifedayo M O Adetifa; Simon Donkor; Rawleigh Howe; Harriet Mayanja-Kizza; W Henry Boom; Hazel M Dockrell; Tom H M Ottenhoff; Mark Hatherill; Alan Aderem; Willem A Hanekom; Thomas J Scriba; Stefan H E Kaufmann; Daniel E Zak; Gerhard Walzl Journal: Am J Respir Crit Care Med Date: 2018-05-01 Impact factor: 30.528
Authors: Ibrahim Abubakar; Francis Drobniewski; Jo Southern; Alice J Sitch; Charlotte Jackson; Marc Lipman; Jonathan J Deeks; Chris Griffiths; Graham Bothamley; William Lynn; Helen Burgess; Bobby Mann; Ambreen Imran; Saranya Sridhar; Chuen-Yan Tsou; Vladyslav Nikolayevskyy; Melanie Rees-Roberts; Hilary Whitworth; Onn Min Kon; Pranab Haldar; Heinke Kunst; Sarah Anderson; Andrew Hayward; John M Watson; Heather Milburn; Ajit Lalvani Journal: Lancet Infect Dis Date: 2018-08-30 Impact factor: 71.421
Authors: Daniel E Zak; Adam Penn-Nicholson; Thomas J Scriba; Ethan Thompson; Sara Suliman; Lynn M Amon; Hassan Mahomed; Mzwandile Erasmus; Wendy Whatney; Gregory D Hussey; Deborah Abrahams; Fazlin Kafaar; Tony Hawkridge; Suzanne Verver; E Jane Hughes; Martin Ota; Jayne Sutherland; Rawleigh Howe; Hazel M Dockrell; W Henry Boom; Bonnie Thiel; Tom H M Ottenhoff; Harriet Mayanja-Kizza; Amelia C Crampin; Katrina Downing; Mark Hatherill; Joe Valvo; Smitha Shankar; Shreemanta K Parida; Stefan H E Kaufmann; Gerhard Walzl; Alan Aderem; Willem A Hanekom Journal: Lancet Date: 2016-03-24 Impact factor: 79.321
Authors: Elisa Nemes; Hennie Geldenhuys; Virginie Rozot; Kathryn T Rutkowski; Frances Ratangee; Nicole Bilek; Simbarashe Mabwe; Lebohang Makhethe; Mzwandile Erasmus; Asma Toefy; Humphrey Mulenga; Willem A Hanekom; Steven G Self; Linda-Gail Bekker; Robert Ryall; Sanjay Gurunathan; Carlos A DiazGranados; Peter Andersen; Ingrid Kromann; Thomas Evans; Ruth D Ellis; Bernard Landry; David A Hokey; Robert Hopkins; Ann M Ginsberg; Thomas J Scriba; Mark Hatherill Journal: N Engl J Med Date: 2018-07-12 Impact factor: 91.245
Authors: Maryam A Amour; Christiaan A Rees; Patricia J Munseri; Jamila Said; Albert K Magohe; Mecky Matee; Elizabeth A Talbot; Robert D Arbeit; Kisali Pallangyo; C Fordham von Reyn Journal: PLoS One Date: 2022-06-24 Impact factor: 3.752
Authors: Harriet N Garlant; Kalaiarasan Ellappan; Matthew Hewitt; Prem Perumal; Simon Pekeleke; Nadina Wand; Jo Southern; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri Vasan; Noyal Mariya Joseph; Karen E Kempsell Journal: Front Immunol Date: 2022-05-20 Impact factor: 8.786
Authors: Humphrey Mulenga; Andrew Fiore-Gartland; Simon C Mendelsohn; Adam Penn-Nicholson; Stanley Kimbung Mbandi; Elisa Nemes; Bhavesh Borate; Munyaradzi Musvosvi; Michèle Tameris; Gerhard Walzl; Kogieleum Naidoo; Gavin Churchyard; Thomas J Scriba; Mark Hatherill Journal: EClinicalMedicine Date: 2022-04-21
Authors: Roberto Dias de Oliveira; Andrea da Silva Santos; Cassia Barbosa Reis; Alessandra de Cássia Leite; Flávia Patussi Correia Sacchi; Rafaele Carla Pivetta de Araujo; Paulo César Pereira Dos Santos; Valeria Cavalcanti Rolla; Leonardo Martinez; Jason Andrews; Julio Croda Journal: Am J Trop Med Hyg Date: 2020-10 Impact factor: 3.707